Immunopathogenesis of tuberculosis: Implications for vaccine development

Respirology

Volumn 13, Issue SUPPL. 3, 2008, Pages

  Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Immunology; Pathogenesis; Tuberculosis; Vaccine

Indexed keywords

ACID PHOSPHATASE; AERAS 402; AERAS 404; BCG VACCINE; CD4 ANTIGEN; COMPLEMENT RECEPTOR; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 7; LIPOARABINOMANNAN; LISTERIOLYSIN; LIVE VACCINE; MANNOSE RECEPTOR; MVA 85 A; MYCOBACTERIUM ANTIGEN; NUCLEIC ACID; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROTEIN CR 3; RECOMBINANT VACCINE; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VACCINIA VACCINE;

CELLULAR IMMUNITY; CHEMOTHERAPY; CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG EFFICACY; GENE SEQUENCE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IN VITRO STUDY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOSOME; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 49749093396     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01350.x     Document Type: Conference Paper

References (51)

1. World Health Organization. World Health Organization Tuberculosis (TB) Accessed April 17 2007.] Available from URL: http://wwwwhoint/tb/en/
2. World Health Organization. XDR-TB, extensively drug-resistant tuberculosis Accessed 5 Dec 2006.] Available from URL: http://www.who.int/ mediacentre/news/notes/2006/np23/en/index.html
3. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 1993 328: 1137 44.
4. Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci. 2004 9: 1136 56.
5. Collins HL, Kaufmann SH. Prospects for better tuberculosis vaccines. Lancet Infect. Dis. 2001 1: 21 8.
6. Dannenberg A. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit. ASM Press, Washington, DC, 2006.
7. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 1990 144: 2771 80.
8. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 1998 66: 1277 81.
9. Vergne I, Chua J, Lee HH, Lucas M, Belisle J et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2005 102: 4033 8.
10. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 2004 304: 1800 4.
11. Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. USA 2003 100: 5437 42.
12. Vergne I, Singh S, Roberts E, Kyei G, Master S et al. Autophagy in immune defense against Mycobacterium tuberculosis. Autophagy 2006 2: 175 8.
13. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006 313: 1438 41.
14. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003 302: 654 9.
15. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004 119: 753 66.
16. Harris J, De Haro SA, Master SS, Keane J, Roberts EA et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007 27: 505 17.
17. Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J. Clin. Immunol. 2007 27: 347 62.
18. Liu PT, Stenger S, Li H, Wenzel L, Tan BH et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006 311: 1770 3.
19. Kaufmann SH, Baumann S, Nasser Eddine A. Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int. J. Tuberc. Lung Dis. 2006 10: 1068 79.
20. Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin. Exp. Immunol. 2006 144: 25 34.
21. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am. J. Respir. Crit. Care Med. 2007 176: 409 16.
22. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr. Mol. Med. 2007 7: 327 37.
23. Garg A, Barnes PF, Roy S, Quiroga MF, Wu S et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur. J. Immunol. 2008 38: 459 69.
24. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007 8: 369 77.
25. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J. Immunol. 2006 177: 1416 20.
26. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 2006 4: 469 76.
27. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995 346: 1339 45.
28. Tsenova L, Harbacheuski R, Sung N, Ellison E, Fallows D et al. BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine 2007 25: 5126 32.
29. Elias D, Britton S, Kassu A, Akuffo H. Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance. Expert Rev. Anti. Infect. Ther. 2007 5: 475 84.
30. Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 2006 124: 683 7.
31. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005 85: 29 38.
32. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 2005 115: 2472 9.
33. Sambandamurthy VK, Jacobs WR, Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 2005 7: 955 61.
34. Asensio JA, Arbues A, Perez E, Gicquel B, Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin. Biol. Ther. 2008 8: 201 11.
35. Aguilar LD, Infante E, Bianco MV, Cataldi A, Bigi F et al. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis. Vaccine 2006 24: 2333 42.
36. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005 85: 47 52.
37. Xing Z, Santosuosso M, McCormick S, Yang TC, Millar J et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther. 2005 5: 485 92.
38. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999 400: 269 71.
39. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 2007 37: 3089 100.
40. Pollock JM, Andersen P. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J. Infect. Dis. 1997 175: 1251 4.
41. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005 366: 1290 5.
42. Palma C, Iona E, Giannoni F, Pardini M, Brunori L et al. The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. Cell. Microbiol. 2007 9: 1455 65.
43. Romano M, Roupie V, Wang XM, Denis O, Jurion F et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 2006 118: 321 32.
44. Behar SM, Woodworth JS, Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev. Vaccines 2007 6: 441 56.
45. Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006 24: 5452 60.
46. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007 6: 723 39.
47. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 2003 9: 533 9.
48. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 2003 198: 705 13.
49. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol. 2007 15: 7 13.
50. Lin MY, Ottenhoff TH. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem. 2008.
51. Zheng H, Lu L, Wang B, Pu S, Zhang X et al. Comparative genomic analysis of attenuated mycobacterium tuberculosis strain H37Ra versus its virulent counterpart H37Rv: Insight into the basis of virulence attenuation. PLOS ONE. 2008 3: e2375.